Screener
Eton Pharmaceuticals, Inc. ETON Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | For the three months ended / March 31, 2026 | For the three months ended / March 31, 2025 |
|---|---|---|
| Total operating expenses | 12,321 | 10,331 |
| Income (loss) from operations | 2,414 | (470) |
| Other expense: | ||
| Interest and other expense, net | (840) | (1,028) |
| Income (loss) before income tax expense | 1,574 | (1,498) |
| Income tax expense | 20 | 74 |
| Net income (loss) | $1,554 | $(1,572) |
| Net income (loss) per share, basic | $0.06 | $(0.06) |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s interest expense?
- Eton Pharmaceuticals, Inc. (ETON) reported interest expense of -$840K in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s interest expense changed year-over-year?
- Eton Pharmaceuticals, Inc.'s interest expense increased by 18.3% year-over-year, from -$1.03M to -$840K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Eton Pharmaceuticals, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude